Editorial: The dark side of the moon- The side effects of therapy in a dynamic era of breast cancer management

Breast Care

Volumn 4, Issue 3, 2009, Pages 144-147

  Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

BREAST CANCER; CANCER SURVIVOR; CANCER THERAPY; COMORBIDITY; DECISION MAKING; EDITORIAL; EVIDENCE BASED MEDICINE; LIFE EXPECTANCY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS;

EID: 67651083470     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000225388     Document Type: Editorial

References (41)

1. Ganz PA, Hahn EE: Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol 2008;26:759-767.
2. De Angelis R, Tavilla A, Verdecchia A, Scoppa S, Hachey M, Feuer EJ, Mariotto AB: Breast cancer survivors in the united states: geographic variability and time trends, 2005-2015. Cancer 2009;115:1954-1966.
3. Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, Tavilla A, Santaquilani M, Sant M: Survival trends in european cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45: 1042-1066.
4. Oeppen J, Vaupel J: Broken limits to life expectancy. Science 2002;296:1029-1031.
5. United Nations Department of Economic and Social Affairs PDWPPTR: 2005.
6. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM: Hodgkin's lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003:225-247.
7. Diehl V, Thomas RK, Re D: Part ii: Hodgkin's lym-phoma--diagnosis and treatment. Lancet Oncol 2004; 5:19-26.
8. Landier W, Bhatia S: Cancer survivorship: a pediat-ric perspective. Oncologist 2008;13:1181-1192.
9. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wieds-wang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
10. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlou-verakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27:2177-2184.
11. Berube S, Provencher L, Robert J, Jacob S, Hebert-Croteau N, Lemieux J, Duchesne T, Brisson J: Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. Breast Cancer Res Treat 2007;106:419-431.
12. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
13. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
14. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M: Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 2008;8:411-417.
15. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/cancer and leukemia group b trial 9741. J Clin Oncol 2003; 21:1431-1439.
16. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD: Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy? Ann Oncol 2008;19:1231-1241.
17. Batist G, Ramakrishnan G, Rao CS, Chandrasekha-ran A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454.
18. Lorusso V, Manzione L, Silvestris N: Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007;18 Suppl 6:vi70-73.
19. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehren-bacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
21. Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD: A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006;7:270-277.
22. Chabner BA, Roberts TG, Jr.: Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72.
23. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004;100:44-52.
24. Wilking N, Jönsson B: A pan-European comparison regarding patient access to cancer drugs. 2005.
25. Peppercorn JM, Weeks JC, Cook EF, Joffe S: Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263-270.
26. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH: Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-139.
27. Kamb A: What's wrong with our cancer models? Nat Rev Drug Discov 2005;4:161-165.
28. Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G: Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies. Eur J Cancer 2009;45:741-746.
29. Greil R: The still long and winding road to neoad-juvant systemic therapy as the standard of care in breast cancer. Breast Care 2006;1:352-357.
30. Tan AR, Swain SM: Therapeutic strategies for triple-negative breast cancer. Cancer J 2008;14:343-351.
31. Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D'Aiuto M, Petrillo A, Lastoria S, Siani C, Comella G, D'Aiuto G: Preoperative weekly cisplatin-epirubicin-paclitaxel with g-csf support in triple-negative large operable breast cancer. Ann Oncol 2009
32. Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL: Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 2009
33. Jones M, Schenkel B, Just J, Fallowfield L: Epoetin alfa improves quality of life in patients with cancer: Results of metaanalysis. Cancer 2004;101:1720-1732.
34. Jenkins VA , Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ: Effects of anastrozole on cognitive performance in postmenopausal women: A randomised, double-blind chemoprevention trial (ibis ii). Lancet Oncol 2008;9:953-961.
35. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL: Memory impairments with adjuvant anastro-zole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-998.
36. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7:192-201.
37. Correa DD, Ahles TA: Neurocognitive changes in cancer survivors. Cancer J 2008;14:396-400.
38. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1432-1439.
39. During MJ, Cao L: VEGF, a mediator of the effect of experience on hippocampal neurogenesis. Curr Alzheimer Res 2006;3:29-33.
40. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma D P, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythro-poiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
41. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM: Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat Rev Drug Discov 2007;6:904-916.